Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human MEF2C Antibodies:
anti-Mouse (Murine) MEF2C Antibodies:
anti-Rat (Rattus) MEF2C Antibodies:
Go to our pre-filtered search.
Cow (Bovine) Polyclonal MEF2C Primary Antibody for WB - ABIN2780048
Shen, Kamp, Gruendling, Higgins: A bifunctional O-GlcNAc transferase governs flagellar motility through anti-repression. in Genes & development 2006
Show all 8 Pubmed References
Human Polyclonal MEF2C Primary Antibody for ICC, IF - ABIN4333449
Wirrig, Hinton, Yutzey: Differential expression of cartilage and bone-related proteins in pediatric and adult diseased aortic valves. in Journal of molecular and cellular cardiology 2011
Show all 4 Pubmed References
Human Monoclonal MEF2C Primary Antibody for FACS, IHC - ABIN1098145
Xu, Cao, Wang, Xu, Chen, Xu: VEGF promotes the transcription of the human PRL-3 gene in HUVEC through transcription factor MEF2C. in PLoS ONE 2011
Show all 2 Pubmed References
Human Monoclonal MEF2C Primary Antibody for FACS, ICC - ABIN4333450
Deczkowska, Matcovitch-Natan, Tsitsou-Kampeli, Ben-Hamo, Dvir-Szternfeld, Spinrad, Singer, David, Winter, Smith, Kertser, Baruch, Rosenzweig, Terem, Prinz, Villeda, Citri, Amit, Schwartz: Mef2C restrains microglial inflammatory response and is lost in brain ageing in an IFN-I-dependent manner. in Nature communications 2017
variable transposon epigenetic silencing underlies the variable mef2ca mutant bone phenotype, and could be a widespread mechanism of phenotypic variability in animals.
Mef2 (show MYEF2 Antibodies) controls skeletal muscle formation after terminal differentiation.
Our study provides new insights in MEF2C conservation and provides the first evidence of mef2cb regulation by both transcriptional and post transcriptional mechanisms.
By selectively inhibiting translational initiation of mef2ca and other mRNAs, eIF4EBP3L reprograms the translational profile of muscle, enabling it to adjust to new environmental conditions.
find no evidence that the phenotypic stability in the wild type is provided by redundancy between mef2ca and its co-ortholog mef2cb, or that it is related to the selector (homeotic) gene function of mef2ca
Mef2ca single mutants have delayed heart development, but form an apparently normal heart. Mef2cb single mutants have a functional heart and are viable adults.
Data show that mef2cb is expressed in the late ventricular region, and is necessary for late myocardial addition to the arterial pole.
the genetic interaction of Tbx5 (show TBX5 Antibodies) and Mef2c is not only required for MYH6 (show MYH6 Antibodies) expression but also essential for the early stages of heart development and survival
Mef2c and Mef2d (show MEF2D Antibodies) are required for proper cardiac gene expression.
MEF2C rs190982 polymorphism has a role in late-onset Alzheimer's disease in Han Chinese
MEF2C mRNA level is up-regulated in both sporadic and SOD1 + ALS patients.
a MEF2C and CEBPA correlation in CML disease progression
Single nucleotide polymorphism in MEF2C gene is associated with major depressive disorder.
we identified novel associations in WLS (show WLS Antibodies) , ARHGAP1 (show ARHGAP1 Antibodies) , and 5' of MEF2C ( P- values < 8x10 - 5 ; false discovery rate (FDR) q-values < 0.01) that were much more strongly associated with BMD (show BEST1 Antibodies) compared to the GWAS SNPs.
Our analysis consistently identified significant sub-networks associated with the interacting transcription factors MEF2C and TWIST1 (show TWIST1 Antibodies), genes not previously associated with spontaneous preterm births , both of which regulate processes clearly relevant to birth timing.
Key role for miR (show MLXIP Antibodies)-214 in modulation of MEF2C-MYOCD (show MYOCD Antibodies)-LMOD1 (show LMOD1 Antibodies) signaling.
Endothelial Mef2c regulates the endothelial actin cytoskeleton and inhibits smooth muscle cell migration into the intima.
The mRNA expressions of PPP3CB (show PPP3CB Antibodies) and MEF2C were significantly up-regulated, and CAMK1 (show CAMK1 Antibodies) and PPP3R1 (show PPP3R1 Antibodies) were significantly down-regulated in mitral regurgitation(MR) patients compared to normal subjects. Moreover, MR patients had significantly increased mRNA levels of PPP3CB (show PPP3CB Antibodies), MEF2C and PLCE1 (show PLCE1 Antibodies) compared to aortic valve disease patients
Findings suggest that a single introduction of the three cardiomyogenic transcription factor (GATA4 (show GATA4 Antibodies), cand TBX5 (show TBX5 Antibodies))genes using polyethyleneimine (PEI)-based transfection is sufficient for transdifferentiation of adipose-derived stem cells (hADSCs) towards the cardiomyogenic lineage.
Deletion and mutation analyses of the promoter of pig myocyte enhancer factor 2 (MEF2 (show MYEF2 Antibodies)) gene showed that MyoD (show MYOD1 Antibodies) and MEF2 (show MYEF2 Antibodies) binding sites within the Mef2c promoter were responsible for the regulation of Mef2c transcription. This study helped to clarify the regulation of Mef2c in muscle differentiation and regeneration.
The cDNA sequence was analyzed and the 5' upstream region of the mef2c gene was isolated from porcine genomic DNA.
analysis of sequence and variations of the bovine myocyte enhancer factor 2C (MEF2C) gene promoter in Bos taurus cattle
Immune challenge in mice lacking Mef2C in microglia results in an exaggerated microglial response and has an adverse effect on mice behaviour.
MEF2C is necessary for Mmp13 (show MMP13 Antibodies) gene expression at the transcriptional level and participates in PTH (show PTH Antibodies)-stimulated Mmp13 (show MMP13 Antibodies) gene expression by increased binding to c-FOS at the AP-1 (show JUN Antibodies) site in the Mmp13 (show MMP13 Antibodies) promoter.
lf5 ChIP-seq revealed that Klf5 (show KLF5 Antibodies) binding overlaps that of MyoD (show MYOD1 Antibodies) and Mef2, and Klf5 (show KLF5 Antibodies) physically associates with both MyoD (show MYOD1 Antibodies) and Mef2. In addition, MyoD (show MYOD1 Antibodies) recruitment was greatly reduced in the absence of Klf5 (show KLF5 Antibodies). These results indicate that Klf5 (show KLF5 Antibodies) is an essential regulator of skeletal muscle differentiation, acting in concert with myogenic transcription factors such as MyoD (show MYOD1 Antibodies) and Mef2.
The authors show here that conditional embryonic deletion of Mef2c in cortical and hippocampal excitatory neurons (Emx1 (show EMX1 Antibodies)-lineage) produces a dramatic reduction in cortical network activity in vivo, due in part to a dramatic increase in inhibitory and a decrease in excitatory synaptic transmission. Perturbing MEF2C function in neocortex can produce autistic- and intellectual disability-like behaviors in mice.
Here, the authors show that loss of Fxn (show FXN Antibodies) in the nervous system in mice also activates an iron/sphingolipid/PDK1 (show PDPK1 Antibodies)/Mef2 pathway, indicating that the mechanism is evolutionarily conserved.
Ca(2 (show CA2 Antibodies)+) signaling pathway increases Nr4a1 (show NR4A1 Antibodies) expression in MA-10 Leydig cells, at least in part, by enhancing the recruitment of coactivator most likely through the MEF2, AP1 (show JUN Antibodies), and CREB (show CREB1 Antibodies) transcription factors thus demonstrating an important interplay between the Ca(2 (show CA2 Antibodies)+) and cAMP pathways in regulating Nr4a1 (show NR4A1 Antibodies) expression.
HDAC5 (show HDAC5 Antibodies) emerges as a cellular conductor of MEF2C and M6a (show GPM6A Antibodies) activity and is regulated by miR (show MLXIP Antibodies)-124 and miR (show MLXIP Antibodies)-9 to control neurite development.
In cardiomyocytes exposed to biomechanical stimulation, FAK (show PTK2 Antibodies) accumulates in the nucleus, binds to and upregulates the transcriptional activity of MEF2c through an interaction with the FAK (show PTK2 Antibodies) focal adhesion targeting (FAT) domain.
In Fmr1 (show FMR1 Antibodies) KO neurons, Mdm2 (show MDM2 Antibodies) is hyperphosphorylated, nuclear localized basally, and unaffected by MEF2 activation, which our data suggest due to an enhanced interaction with Eukaryotic Elongation Factor (show TSFM Antibodies) 1alpha (EF1alpha), whose protein levels are elevated in Fmr1 (show FMR1 Antibodies) KO. Expression of a dephosphomimetic of Mdm2 (show MDM2 Antibodies) rescues PSD-95 (show DLG4 Antibodies) ubiquitination, degradation and synapse elimination in Fmr1 (show FMR1 Antibodies) KO neurons.
two MEF2 sites in the enhancer function cooperatively due to bridging of the MEF2C-bound sites by the SAP (show APCS Antibodies) domain-containing co-activator protein myocardin (show MYOCD Antibodies)
This locus encodes a member of the MADS box transcription enhancer factor 2 (MEF2) family of proteins, which play a role in myogenesis. The encoded protein, MEF2 polypeptide C, has both trans-activating and DNA binding activities. This protein may play a role in maintaining the differentiated state of muscle cells. Mutations and deletions at this locus have been associated with severe mental retardation, stereotypic movements, epilepsy, and cerebral malformation. Alternatively spliced transcript variants have been described.
myocyte-specific enhancer factor 2C
, myocyte enhancer factor 2C
, myocyte-specific enhancer factor 2C-like
, MADS box transcription enhancer factor 2, polypeptide C
, MADS box transcription enhancer factor 2, polypeptide C (myocyte enhancer factor 2C)
, Myocyte enhancer factor 2C protein
, myocyte enhancer factor 2c